About Indaptus Therapeutics, Inc. Common Stock
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
Market Cap
$0.01B
Employees
7
Listed Since
August 4, 2021
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.indaptusrx.comPhone
(646) 427-2727
Headquarters
3 COLUMBUS CIRCLE
NEW YORK, NY 10019
CIK
0001857044